What question did this study set out to answer?

To determine whether the selective endothelin ETA receptor antagonist BQ-123 inhibits neointima formation in vivo following balloon angioplasty.

May 1, 1995Cardiovascular Research

Selective ETA receptor antagonism with BQ-123 is insufficient to inhibit angioplasty induced neointima formation in the rat

View Full Paper

Ask AI

Bookmark

Why the study?

Does the ETA receptor selective antagonist BQ-123 inhibit neointima formation following balloon angioplasty in rats?

Population

Rats undergoing left common carotid artery balloon angioplasty

Design

Preclinical

Authors

SDSD DouglasChildren's Hospital of Philadelphia LVLynne M. Vickery‐ClarkNew Frontier CLCalvert LoudenAstraZeneca (United Kingdom)

Discussion

Member takes

Implication

Does not support ETA antagonism to limit restenosis; leaves open ETB receptor contributions in experimental angioplasty models.

Key Points

To determine whether the selective endothelin ETA receptor antagonist BQ-123 inhibits neointima formation in vivo following balloon angioplasty.
Subjected rats to balloon angioplasty of the left common carotid artery.
Administered BQ-123 acutely via intra-arterial infusion (0.1 mg·kg⁻¹·min⁻¹ for 1 hour before and 1 hour after injury).
Administered BQ-123 chronically via intraperitoneal injection (2.5 mg·kg⁻¹ twice daily) or continuous intraperitoneal infusion (0.8 and 8 mg·kg⁻¹·day⁻¹).
Acute intra-arterial infusion of BQ-123 did not produce a significant reduction in post-angioplasty neointima formation.
Chronic intraperitoneal administration, across both intermittent bolus and continuous infusion regimens, showed no significant inhibitory effect on neointima development.

Structured PICO

Does the ETA receptor selective antagonist BQ-123 inhibit neointima formation following balloon angioplasty in rats?

Population

Rats undergoing left common carotid artery balloon angioplasty

Intervention

BQ-123 (acute administration: 0.1 mg/kg/min intra-arterial infusion for 1 h before and 1 h after angioplasty; or chronic administration: bolus intraperitoneal injection, 2.5 mg/kg twice daily; continuous intraperitoneal infusion, 0.8 and 8 mg/kg/d)

Outcome

Degree of neointima formationsurrogate

Selective ETA receptor antagonism with BQ-123 does not inhibit angioplasty-induced neointima formation in rats, suggesting the ETB receptor subtype may be implicated in this pathogenesis.

Cite This Study

Douglas et al. (1995) studied this question.

synapsesocial.com/papers/6a916f94d73fb5289dab5c65 https://doi.org/10.1016/s0008-6363(96)88634-2

View Full Paper

Ask AI

Bookmark

Selective ETA receptor antagonism with BQ-123 is insufficient to inhibit angioplasty induced neointima formation in the rat

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Selective ETA receptor antagonism with BQ-123 is insufficient to inhibit angioplasty induced neointima formation in the rat

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider